Checkpoint inhibitor therapy

Jan 18, 2018

Compugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid Tumors

Dec 29, 2017

CStone's anti-CTLA-4 antibody CS1002 filed for clinical trial approval in Australia

Nov 13, 2017

Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs

Nov 02, 2017

Epic Sciences Launches Single-Cell Microsatellite and Chromosomal Instability Genomic Analysis

Oct 20, 2017

CStone Pharmaceuticals Announces Dosing the First Patient of CS1001: China's First Fully Human, Full-length Anti-PD-L1 Monoclonal Antibody

Oct 12, 2017

Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients

Sep 25, 2017

ImaginAb Inc. Announces Strategic Collaboration with Boehringer Ingelheim to Develop New Technology for Monitoring Anti-tumor Activity of the Immune System